Shanghai - Delayed Quote CNY

InnoCare Pharma Limited (688428.SS)

20.56
+0.11
+(0.54%)
At close: 3:00:01 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,009,448
1,009,448
738,537
625,404
1,043,033
Cost of Revenue
138,441
138,441
128,435
143,397
65,667
Gross Profit
871,007
871,007
610,102
482,007
977,366
Operating Expense
1,396,791
1,396,791
1,262,609
1,213,147
1,143,605
Operating Income
-525,784
-525,784
-652,507
-731,140
-166,239
Net Non Operating Interest Income Expense
137,801
137,801
157,264
119,869
132,493
Pretax Income
-452,593
-452,593
-644,206
-893,727
-20,121
Tax Provision
263
263
1,426
0
46,558
Net Income Common Stockholders
-440,633
-440,633
-631,263
-886,593
-64,545
Diluted NI Available to Com Stockholders
-440,633
-440,633
-631,263
-886,593
-64,545
Basic EPS
-0.26
-0.26
-0.37
-0.60
-0.05
Diluted EPS
-0.26
-0.26
-0.37
-0.60
-0.05
Basic Average Shares
1,690,850
1,690,850
1,687,470
1,479,565
1,366,261
Diluted Average Shares
1,690,850
1,690,850
1,687,470
1,479,565
1,366,261
Total Expenses
1,535,232
1,535,232
1,391,044
1,356,544
1,209,272
Net Income from Continuing & Discontinued Operation
-440,633
-440,633
-631,263
-886,593
-64,545
Normalized Income
-439,511.75
-439,511.75
-622,987.50
-893,050
-69,570.75
Interest Income
171,589
171,589
192,333
136,914
135,135
Interest Expense
33,788
33,788
35,069
17,045
2,642
Net Interest Income
137,801
137,801
157,264
119,869
132,493
EBIT
-418,805
-418,805
-609,137
-876,682
-17,479
EBITDA
-312,545
-312,545
-516,516
-808,279
16,232
Reconciled Cost of Revenue
138,441
138,441
128,435
143,397
65,667
Reconciled Depreciation
106,260
106,260
92,621
68,403
33,711
Net Income from Continuing Operation Net Minority Interest
-440,633
-440,633
-631,263
-886,593
-64,545
Total Unusual Items Excluding Goodwill
-1,495
-1,495
-11,034
6,457
6,701
Total Unusual Items
-1,495
-1,495
-11,034
6,457
6,701
Normalized EBITDA
-311,050
-311,050
-505,482
-814,736
9,531
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-373.75
-373.75
-2,758.50
0
1,675.25
12/31/2021 - 9/21/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6XC.F Soleno Therapeutics, Inc.
64.85
+1.25%
 
25I.SG ImmuPharma PLC
0.0265
-10.17%
 
22Z.SG Zealand Pharma A/S
56.18
-6.30%
 
BT3.BE Lineage Cell Therapeutics Inc
0.4060
+5.73%
 
BSFAF BSF Enterprise Plc
0.0584
0.00%
 
328.SG MeiraGTx Holdings PLC
4.7600
-0.83%
 
GNFTF Genfit S.A.
3.5400
0.00%
 
CLAZF Claritas Pharmaceuticals, Inc.
0.0001
0.00%
 
XUPB.F Genfit S.A.
3.7800
-0.53%
 
SCP.F Scancell Holdings plc
0.0825
-13.16%